Literature DB >> 18065748

In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".

Angela DeMichele, Phyllis Gimotty, Jeffrey Botbyl, Richard Aplenc, Theresa Colligon, Andrea S Foulkes, Timothy R Rebbeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18065748     DOI： 10.1200/JCO.2006.10.1485

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.

Authors:  WeiYing Li; WenTao Yue; LiNa Zhang; XiaoTing Zhao; Li Ma; XueHui Yang; ChunYan Zhang; Yue Wang; Meng Gu
Journal:  Lung       Date:  2011-11-23       Impact factor: 2.584

2.  Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

Authors:  Priya P Gor; H Irene Su; Robert J Gray; Phyllis A Gimotty; Michelle Horn; Richard Aplenc; William P Vaughan; Martin S Tallman; Timothy R Rebbeck; Angela DeMichele
Journal:  Breast Cancer Res       Date:  2010-05-10       Impact factor: 6.466

3.  Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.

Authors:  Gaurav Agarwal; Sonam Tulsyan; Punita Lal; Balraj Mittal
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

4.  [Relationship between the genetic polymorphisms of phase I and II drug-metabolizing enzymes, as well as the outcome of chemotherapy in advanced non-small cell lung cancer].

Authors:  Weiying Li; Wentao Yue; Xuehui Yang; Chunyan Zhang; Yue Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-11

5.  Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.

Authors:  M E Madeleine van der Perk; Linda Broer; Yutaka Yasui; Leslie L Robison; Melissa M Hudson; Joop S E Laven; Helena J van der Pal; Wim J E Tissing; Birgitta Versluys; Dorine Bresters; Gertjan J L Kaspers; Andrica C H de Vries; Cornelis B Lambalk; Annelies Overbeek; Jacqueline J Loonen; Catharina C M Beerendonk; Julianne Byrne; Claire Berger; Eva Clemens; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Monica Muraca; Melanie Kaiser; Tomáš Kepák; Jarmila Kruseova; Dalit Modan-Moses; Claudia Spix; Oliver Zolk; Peter Kaatsch; Jesse H Krijthe; Leontien C M Kremer; Russell J Brooke; Jessica L Baedke; Ron H N van Schaik; John N van den Anker; André G Uitterlinden; Annelies M E Bos; Flora E van Leeuwen; Eline van Dulmen-den Broeder; Anne-Lotte L F van der Kooi; Marry M van den Heuvel-Eibrink
Journal:  Cancers (Basel)       Date:  2021-09-13       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.